Mangoceuticals (MGRX) Cash & Equivalents (2023 - 2026)

Mangoceuticals (MGRX) posted Cash & Equivalents of $174562.0 for Q1 2026, down 88.26% sequentially from $1.5 million in Q4 2025.

Mangoceuticals (MGRX) Cash & Equivalents (2023 - 2026) Analysis & Trends

Mangoceuticals has reported Cash & Equivalents for 4 years, with the latest figure at $174562.0 in Q1 2026.

Quarterly Cash & Equivalents changed N/A year-over-year to $174562.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $174562.0 (changed N/A YoY) and the FY2025 annual result came in at $1.5 million, changed N/A from the prior year.
Cash & Equivalents declined to $174562.0 in Q1 2026 per MGRX's latest filing, from $1.5 million in the prior quarter.
Over five years, Cash & Equivalents peaked at $1.5 million in Q4 2025 and troughed at $15305.0 in Q1 2024.
A 4-year average of $603802.8 and a median of $456784.0 in 2023 frame the typical range for Cash & Equivalents.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Cash & Equiv. (Qtr)
1	Veeva Systems	39.72 Bn	32.40 Bn	662.02 Mn	1.90 Bn
2	BrightSpring Health Services	12.19 Bn	11.64 Bn	492.75 Mn	550.38 Mn
3	Healthequity	8.79 Bn	8.52 Bn	256.31 Mn	265.37 Mn
4	10x Genomics	7.31 Bn	6.76 Bn	112.50 Mn	502.51 Mn
5	Hinge Health	7.10 Bn	6.71 Bn	183.95 Mn	286.22 Mn
6	MiniMed	5.66 Bn	5.36 Bn	480.00 Mn	298.00 Mn
7	Waystar Holding	4.76 Bn	4.56 Bn	221.99 Mn	12.65 Mn
8	Doximity	4.46 Bn	3.77 Bn	132.93 Mn	273.60 Mn
9	Heartflow	3.66 Bn	3.28 Bn	53.19 Mn	246.80 Mn
10	Mangoceuticals	9.55 Mn	9.30 Mn	44,215.00	228,688.00

Download Data